The Similac necrotizing enterocolitis lawsuit is a massive wave of litigation against Abbott Laboratories alleging that its cow’s milk-based infant formulas, including Similac Special Care and Similac Human Milk Fortifier, significantly increase the risk of necrotizing enterocolitis in premature infants. As of March 2026, 779 cases are pending in multidistrict litigation (MDL No. 3026) in the U.S. District Court for the Northern District of Illinois, overseen by U.S. District Judge Rebecca Pallmeyer.
The litigation has already produced a staggering $495 million jury verdict against Abbott in a Missouri state court, yet the company has also won three consecutive bellwether cases in federal court, creating a deeply uncertain landscape for families weighing whether to file claims. The core allegation across these lawsuits is straightforward: Abbott and co-defendant Mead Johnson (owned by Reckitt Benckiser, maker of Enfamil) knew or should have known that feeding cow’s milk-based formula to premature infants carried a heightened risk of NEC, a devastating intestinal condition that can be fatal, and they failed to warn parents and healthcare providers. For families like that of plaintiff Margo Gill, whose infant daughter developed NEC after receiving Similac in a neonatal intensive care unit, the consequences were life-altering. No global settlement has been reached, but three new bellwether trials are scheduled between August 2026 and February 2027, and plaintiffs’ attorneys are hoping a resolution may emerge before those trials begin. This article covers the current state of the MDL, major verdicts and defense wins, what the upcoming bellwether trials mean for families with pending claims, and practical considerations for anyone evaluating whether to pursue a Similac NEC lawsuit.
Table of Contents
- What Is the Similac NEC Lawsuit and Who Can File a Claim?
- Major Jury Verdicts in the NEC Formula Litigation
- Abbott’s Federal Court Winning Streak and What It Means
- Upcoming Bellwether Trials and the Path to a Possible Settlement
- Challenges Facing Plaintiffs in NEC Formula Cases
- The Role of Mead Johnson and Enfamil in the Broader Litigation
- What to Expect From the NEC Lawsuit in 2026 and Beyond
- Conclusion
- Frequently Asked Questions
What Is the Similac NEC Lawsuit and Who Can File a Claim?
The Similac NEC lawsuit targets abbott Laboratories for manufacturing and marketing cow’s milk-based infant formulas that plaintiffs say are unreasonably dangerous for premature babies. Necrotizing enterocolitis is a condition in which intestinal tissue becomes inflamed and begins to die. It primarily affects preterm infants, and the mortality rate is significant. The lawsuits allege that Abbott had access to medical literature linking cow’s milk-based formulas to elevated NEC risk in premature infants but continued selling products like Similac Special Care to NICUs without adequate warnings. To file a claim, a plaintiff generally needs to show that a premature infant was fed a Similac product (or in the broader MDL, an Enfamil product from Mead Johnson) in a hospital setting and subsequently developed NEC.
The cases span a range of outcomes, from infants who required emergency surgery and suffered lasting complications to wrongful death claims where babies did not survive. The distinction matters legally because compensatory and punitive damages vary enormously depending on severity. The $495 million Missouri verdict, for example, involved an infant who survived but suffered serious harm, while a separate $60 million verdict in Illinois involved a premature infant who died after being fed Enfamil preterm formula. It is worth noting that these lawsuits are not a traditional class action where all plaintiffs share a single outcome. The MDL consolidates pretrial proceedings for efficiency, but each case is ultimately decided on its own facts. That means individual results will vary widely depending on the specific product used, the infant’s medical history, and the strength of expert testimony linking the formula to NEC.
Major Jury Verdicts in the NEC Formula Litigation
The largest verdict to date came in July 2024, when a St. Louis, Missouri state court jury awarded plaintiff Margo Gill $495 million, broken down as $95 million in compensatory damages and $400 million in punitive damages against Abbott Laboratories. The punitive damages figure reflected the jury’s conclusion that Abbott’s conduct went beyond negligence into something more culpable. Gill’s infant daughter developed NEC after being given Similac in the NICU, and the trial presented evidence that Abbott was aware of the risks but prioritized market share over patient safety. Earlier that same year, in March 2024, a jury in St. Clair County, Illinois awarded $60 million in damages against Mead johnson (Reckitt Benckiser) in a case involving a premature infant who died from NEC after being fed Enfamil preterm formula.
Together, these two state court verdicts signaled that juries were receptive to the argument that formula manufacturers bore responsibility for NEC injuries. However, these verdicts come with important caveats. Large jury awards are frequently reduced on appeal or through post-trial motions. Punitive damages in particular face constitutional scrutiny, and courts have historically trimmed awards they deem disproportionate to compensatory damages. Plaintiffs who point to the $495 million number as a benchmark should understand that the final payout in that case could look very different after appellate review. The verdicts are significant as litigation signals, but they do not guarantee similar outcomes for other families.
Abbott’s Federal Court Winning Streak and What It Means
While state court juries have sided with plaintiffs, the federal MDL in Chicago has told a very different story. Abbott has won three consecutive bellwether cases in the federal proceedings, raising serious questions about the viability of the broader plaintiff pool’s claims under federal evidentiary standards. In May 2025, a federal judge threw out a case against Abbott days before trial was scheduled to begin, excluding the plaintiff’s expert testimony on causation. In July 2025, a second federal bellwether was dismissed on the same grounds. Then in October 2025, a third bellwether went to a jury, which ruled in Abbott’s favor. The expert testimony issue is central to understanding the split between state and federal outcomes.
Federal courts apply the daubert standard for admitting expert testimony, which requires that scientific opinions be based on reliable methodology and sufficient data. State courts in Missouri and Illinois apply different (often more permissive) standards for expert testimony. Plaintiffs whose causation experts cannot survive Daubert challenges in federal court face an uphill battle regardless of how sympathetic their facts may be. There is a meaningful silver lining for the plaintiff side. In March 2025, a federal judge allowed a new trial in one of the previously decided cases, keeping the litigation alive despite the defense winning streak. This decision suggested that at least some federal judges see unresolved questions in the evidence, which could give future bellwether plaintiffs a better chance if they can present stronger or different expert testimony.
Upcoming Bellwether Trials and the Path to a Possible Settlement
Three new Similac NEC lawsuits have been selected for bellwether trials in the federal MDL, scheduled for August 3, 2026, November 2, 2026, and February 1, 2027. These cases focus on severe NEC injuries and wrongful death claims linked to Similac Special Care, Similac Human Milk Fortifier, and other Similac products. The selection of cases involving the most serious injuries is deliberate. Bellwether trials are designed to test the strongest claims and establish a framework for how similar cases might resolve. The timing matters because plaintiffs’ attorneys have expressed hope that a global settlement could materialize before the August 2026 trial begins. Settlements in mass tort litigation often emerge after enough bellwether results give both sides a realistic picture of trial outcomes.
Right now, the picture is mixed: plaintiffs have massive state court wins, but Abbott has a clean sweep in federal court. If one or more of the 2026 bellwethers produces a plaintiff verdict in federal court, it would significantly increase settlement pressure on Abbott. If Abbott continues winning, the calculus shifts further in the company’s favor. For families currently weighing whether to file, the tradeoff is between waiting for more clarity and risking statute of limitations issues. Most states impose deadlines for filing personal injury and wrongful death claims, and those clocks do not pause simply because an MDL exists. Consulting with an attorney sooner rather than later is advisable even if the overall litigation timeline remains uncertain.
Challenges Facing Plaintiffs in NEC Formula Cases
The single biggest challenge for plaintiffs is proving causation to a federal court’s satisfaction. NEC is a multifactorial condition, meaning premature infants can develop it for reasons unrelated to formula, including gut immaturity, bacterial infection, and reduced blood flow to the intestines. Abbott’s defense has consistently argued that plaintiffs cannot isolate cow’s milk-based formula as the cause of NEC in any individual infant, and federal judges have agreed in several instances by excluding plaintiff expert witnesses. This does not mean the science is settled against plaintiffs. Peer-reviewed research has found associations between cow’s milk-based formula and NEC in preterm infants, and medical organizations including the World Health Organization have long recommended human breast milk as the preferred nutrition for premature babies.
The issue is the gap between epidemiological association and the specific causation standard required in federal court. Showing that a product increases risk across a population is different from proving it caused harm in a particular baby, and bridging that gap requires expert testimony that can withstand rigorous judicial scrutiny. Families should also be aware that even successful cases take years to resolve. The MDL was established several years ago, and the first bellwether trials are only now producing results. Attorneys typically handle these cases on a contingency fee basis, meaning families do not pay upfront, but the emotional toll of prolonged litigation involving an infant’s serious injury or death should not be underestimated.
The Role of Mead Johnson and Enfamil in the Broader Litigation
While the Similac lawsuits against Abbott get the most attention, Mead Johnson (owned by Reckitt Benckiser) faces parallel claims over its Enfamil line of preterm infant formulas. The $60 million verdict in March 2024 was against Mead Johnson, not Abbott, and the MDL includes claims against both companies. The legal theories are essentially identical: both defendants allegedly knew their cow’s milk-based formulas posed elevated NEC risks to premature infants and failed to provide adequate warnings.
For families whose infants received Enfamil rather than Similac, the litigation path is largely the same. The MDL consolidates claims against both manufacturers, and the bellwether trial results for one defendant can influence settlement dynamics for the other. However, each company has its own legal strategy and risk tolerance, so it is possible that one might settle while the other continues fighting.
What to Expect From the NEC Lawsuit in 2026 and Beyond
The next twelve months will likely determine the trajectory of the entire NEC formula litigation. If plaintiffs can secure a federal court verdict in one of the three upcoming bellwether trials, it would break Abbott’s winning streak and dramatically shift settlement negotiations. If Abbott continues to prevail, the MDL could face a slow attrition as federal cases are dismissed or resolved on unfavorable terms, even while state court filings continue.
Regardless of how the bellwethers play out, the underlying public health question is not going away. Hospitals and NICUs have already begun shifting practices toward greater use of donor human milk and away from routine cow’s milk-based formula for the most vulnerable premature infants. Whether the legal system ultimately holds manufacturers accountable or not, the litigation has already changed the conversation about what premature babies are fed and who bears responsibility when things go wrong.
Conclusion
The Similac NEC lawsuit stands at a critical juncture. Families have seen both extraordinary jury verdicts, including a $495 million award in Missouri, and frustrating federal court losses where expert testimony has been excluded.
With 779 cases pending in the MDL and three new bellwether trials set for late 2026 and early 2027, the coming months will shape whether Abbott faces serious settlement pressure or continues to fight case by case. For parents of premature infants who developed NEC after receiving Similac or other cow’s milk-based formulas, the most important step is consulting with an attorney experienced in NEC litigation before any applicable statute of limitations expires. The legal landscape is genuinely uncertain, but the size of the verdicts and the volume of pending cases confirm that courts are taking these claims seriously, even as the path to resolution remains long and contested.
Frequently Asked Questions
What is necrotizing enterocolitis and why is it linked to infant formula?
Necrotizing enterocolitis (NEC) is a serious intestinal disease primarily affecting premature infants, in which bowel tissue becomes inflamed and can die. Research has shown an association between cow’s milk-based infant formulas and increased NEC risk in preterm babies, which is the foundation of the lawsuits against Similac and Enfamil manufacturers.
How much are Similac NEC lawsuits worth?
Verdicts have ranged widely. The largest to date is a $495 million jury award in Missouri state court against Abbott Laboratories in July 2024. A separate $60 million verdict was awarded against Mead Johnson in Illinois. However, individual case values depend on the severity of injury, and federal court bellwether cases have resulted in defense verdicts, making average settlement values difficult to predict.
Has there been a settlement in the Similac NEC lawsuit?
No global settlement has been reached as of March 2026. Plaintiffs’ attorneys have expressed hope that settlement talks may progress before the August 2026 bellwether trial, but Abbott has shown a willingness to litigate aggressively, particularly after winning three consecutive federal bellwether cases.
Why has Abbott won in federal court but lost in state court?
The primary difference involves evidentiary standards. Federal courts apply the Daubert standard for expert testimony, which requires reliable scientific methodology. Some federal judges have excluded plaintiffs’ causation experts under this standard. State courts in Missouri and Illinois apply different rules that have allowed the same or similar expert testimony to reach juries.
What is the deadline to file a Similac NEC lawsuit?
Statutes of limitations vary by state and depend on factors including the date of injury and when the connection to formula was discovered. Some states have specific rules extending deadlines for claims involving minors. Because these deadlines are strict, families should consult an attorney promptly rather than waiting for the MDL to reach a resolution.
Which Similac products are involved in the lawsuit?
The lawsuits primarily involve Similac Special Care, Similac Human Milk Fortifier, and other Similac products designed for premature or low-birth-weight infants. These products were typically administered in neonatal intensive care units rather than purchased by parents at retail stores.